v3.26.1
BALANCE SHEET COMPONENTS (Tables)
6 Months Ended
Jun. 30, 2026
BALANCE SHEET COMPONENTS  
Schedule of reconciliation of cash and cash equivalents and restricted cash

​

​

​

​

​

​

​

​

​

  ​ ​ ​

June 30, 2026

  ​ ​ ​

June 30, 2025

​

​

(amounts, in thousands)

Cash and cash equivalents

​

$

4,413

​

$

10,204

Restricted cash

​

 

1,522

​

 

1,522

Total cash, cash equivalents, and restricted cash

​

$

5,935

​

$

11,726

Schedule of inventories - net

​

​

​

​

​

​

​

​

​

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

​

​

(amounts, in thousands)

Raw materials

​

$

658

​

$

751

Work in process

​

 

985

​

 

1,014

Finished goods

​

​

2,043

​

​

3,528

Inventories

​

​

3,686

​

​

5,293

Less reserve

​

 

—

​

 

(12)

Inventories - net

​

$

3,686

​

$

5,281

Schedule of property and equipment

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Depreciation/

​

​

​

​

​

​

​

​

Amortization

​

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

  ​ ​ ​

Period

​

​

(amounts, in thousands)

​

​

Furniture and fixtures

​

$

1,536

​

$

1,532

 

7 years

Equipment and computers

​

 

5,064

​

 

5,129

 

3 to 7 years

Leasehold improvements

​

 

6,304

​

 

6,308

 

Lesser of term of lease or estimated useful life

​

​

 

12,904

​

 

12,969

​

​

Less accumulated depreciation and amortization

​

 

(5,732)

​

 

(5,146)

 

  ​

Property and equipment - net

​

$

7,172

​

$

7,823

 

  ​

Schedule of patents - net

​

​

​

​

​

​

​

​

​

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

​

​

(amounts, in thousands)

Patent applications pending

​

$

1,117

​

$

1,356

Patents issued

​

 

3,298

​

 

3,298

Less accumulated amortization of patents issued

​

 

(1,551)

​

 

(1,428)

Patents - net

​

$

2,864

​

$

3,226

Schedule of Patent amortization expense related to patents issued

​

​

​

​

​

​

​

(amounts, in thousands)

Remainder of 2026

  ​ ​ ​

$

122

2027

​

 

240

2028

​

 

227

2029

​

 

227

2030

​

 

227

Thereafter

​

 

704

Scheduled amortization of patents issued

​

$

1,747

Schedule of accrued expenses and other current liabilities

​

​

​

​

​

​

​

​

​

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

​

​

(amounts, in thousands)

Accrued salaries and commissions

​

$

3,381

​

$

3,413

Clinical studies

​

 

651

​

 

522

Deferred revenue and contract liabilities

​

 

1,139

​

 

182

Professional fees

​

​

472

​

​

856

Royalties

​

​

558

​

​

271

Goods received not invoiced

​

​

95

​

​

150

Other

​

 

987

​

 

905

Accrued expenses and other current liabilities

​

$

7,283

​

$

6,299

​